T-Cell Therapy Market To Surpass USD 21.28 Billion by 2029, Growing at a CAGR of 18.55%

PRESS RELEASE
Published April 12, 2023

The world class T-Cell Therapy advertising report explains market segmentation in the most-detailed pattern as well as conducts thorough analysis of patents and major market players to present a competitive landscape. To serve the clients with the best market report in the industry, an expert team of skilled analysts, dynamic forecasters and knowledgeable researchers work carefully while preparing this report. Getting well-versed with the most relevant product and market information helps businesses accomplish sustainable growth in the market. To overcome the business challenges and drive the business faster in the Healthcare industry, T-Cell Therapy Market research report is an ideal key.

T cell therapy is a type of immunotherapy that is used to treat cancer by altering T cells, which are part of the immune system. T cells were taken from a person’s blood sample and then genetically engineered to develop specific structures on their surface known as chimeric antigen receptors (CARs). T-cell therapy is currently approved by the FDA as standard of care for certain types of aggressive, relapsed, or refractory non-Hodgkin lymphoma, such as diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma. T-cell treatment is also approved for patients under the age of 25 who have relapsed or refractory acute lymphoblastic leukemia.

Data Bridge Market Research analyses that the thymus (T)-cell therapy market was valued at USD 5.45 billion in 2021 and is expected to reach USD 21.28 billion by 2029, registering a CAGR of 18.55% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request for a sample copy of this T-Cell Therapy Market Report at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-t-cell-therapy-market

T-Cell Therapy Market Competitive Outlook

Acquisitions, partnerships, and collaborations were among the market’s inorganic growth strategies. As a result of these activities, T-Cell Therapy market participants have been able to increase their clientele and earnings.

Some of the major players operating in the thymus (T)-cell therapy market are:

Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Novartis AG (Switzerland)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Bristol-Myers Squibb Company (US)
Merck KGaA (Germany)
Aurora Health Care (US)
bluebird bio, Inc. (US)
Amgen Inc. (US)
Gilead Sciences, Inc. (US)
Aurora Biopharma. (US)
Fate Therapeutics (US)
Mustang Bio (US)
Sorrento Therapeutics Inc. (US)
TCR² Therapeutics (US)
Bayer AG (Germany)
Bellicum Pharmaceuticals Inc. (US)
AstraZeneca (UK)
Johnson & Johnson Private Limited (US)

T-Cell Therapy Market Segmentation:

The market research observes a number of significant segments and sub-segments based on requirement, application, end users, and geography to acquire an understanding of the market.

The thymus (T)-cell therapy market is segmented on the basis of modality, therapy, indication, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Modality

Research

Commercialized

Therapy

CAR T-cell Based

T Cell Receptor (TCR) Based

Tumor Infiltrating Lymphocytes (TIL) Based

Indication

Hematologic Malignancies

Lymphoma

Leukemia

Myeloma

Solid Tumors

Melanoma

Brain and Central Nervous System

Liver Cancer

Others

Others

End-Users

Hospitals

Specialty Clinics

Homecare

Others

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Do Read Whole Report Summary of the T-Cell Therapy Market at: https://www.databridgemarketresearch.com/reports/global-t-cell-therapy-market

T-Cell Therapy Market Study and Strategies Carry Out as below:

The report contains a detailed assessment of major industry players operating in the T-Cell Therapy Market.

It covers latest development strategies, value chain analysis, and key growth prospects accepted by crucial manufacturers of the market.

It studies growth-oriented micro and macro-economic indicators.

Assessment of recent T-Cell Therapy market size, forecast information, and technology improvements within the industry

The research describes current information influencing the strategic scenario and imminent industry trends in the T-Cell Therapy Market.

This report estimates the market size and its contribution to the parent market

Assessment of T-Cell Therapy market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis

2022-2029 Latest Updated Research Report with Overview, Definition, TOC, Market Key Players Update

The report includes top market players updated in 2022-2029 with their latest business strategy, sales volume and revenue analysis

Drivers

High prevalence rate of cancer

The rise in prevalence rate of cancer will act as a major driver that will result in the expansion of the growth rate of the market. Increasing tobacco use, unhealthy eating habits and sedentary lifestyles of people, all of which contribute to an increased risk of cancer. As a result, the market is expected to rise in response to the rising global prevalence of cancer. According to the American Cancer Society, 28.4 million new cancer cases are expected to be diagnosed in 2040. This, together with an increase in the number of people diagnosed with bone marrow and blood-forming tissue illnesses, is one of the key factors driving demand for T-cell therapy.

Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of thymus (T)-cell therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness and surging geriatric population will expand the thymus (T)-cell therapy market. Additionally, favourable reimbursement policies and growing government favourable initiatives will result in the expansion of thymus (T)-cell therapy market.

Opportunities

Increase in the number of research and development activities       

Moreover, the market’s growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the thymus (T)-cell therapy market growth. The widespread spread of coronavirus illness (COVID-19) has prompted researchers all around the world to consider T-cell therapy as a treatment option for high-risk patients. T-cell therapies were also recently approved by the US Food and Drug Administration (USFDA) to treat children with acute lymphoblastic leukemia (ALL) and adults with advanced lymphomas. As a result, producers are expected to benefit from attractive prospects and the market will increase.

New product launches

Over the projected period, new product launches by industry players in the thymus (T)-cell therapy market due to high demand from the general public are estimated to promote new market opportunities. For instance, the US Food and Drug Administration authorized Tecartus (brexucabtagene autoleucel), a cell-based gene therapy, in July 2020 for the treatment of adult patients with mantle cell lymphoma (MCL) who have not responded to or relapsed after prior treatments. The FDA has approved Tecartus, a chimeric antigen receptor (CAR) T cell therapy, as the first cell-based gene therapy for MCL.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the thymus (T)-cell therapy market growth during the forecast period.

What does this Report provide?

How the T-Cell Therapy market is evolving?

What is driving and restraining T-Cell Therapy dynamics?

How will each T-Cell Therapy’s submarket will segment grow over the forecast period and how much sales will these submarkets account for in 2029?

How will market shares of each of the T-Cell Therapy submarkets develop from 2022 to 2029?

Which T-Cell Therapy submarket will be the main driver of the overall market from 2022 to 2029?

How will political regulatory factors influence regional T-Cell Therapy markets and submarkets?

Who are the leading players and what are the prospects over the forecast period?

What are the moving and arising advances expected to influence the advancement of the T-Cell Therapy market?

The research includes historical data from 2018 to 2022 and forecasts until 2029, which offerings the report openly for industry executives, marketing, sales and product managers looking for key industry data in simply accessible documents; It is a appreciated resource for consultants, analysts and stakeholders. Tables and graphs

Get Access to the Complete TOC for T-Cell Therapy Market here: https://www.databridgemarketresearch.com/toc/?dbmr=global-t-cell-therapy-market

T-Cell Therapy Market report provides estimation and analysis of the rising trends along with major drivers, restraints, challenges and opportunities in the Healthcare industry. Besides, the report systematically gathers the information about influencing factors for the Healthcare industry which contains customer behavior, emerging trends, product usage, and brand positioning. This market report has vast information about the Healthcare industry with many important facts and figures, expert opinions, and the most recent development across the sphere. By applying business intelligence, T-Cell Therapy Market report is organized which provides thorough and extensive market insights.

Related Report:

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Types (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Target Antigen (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, Egfrvlll, Others), Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasts, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular, Carcinoma, Colorectal Cancer, Others) – Industry Trends and Forecast to 2030. https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-market

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Corporatesales@databridgemarketresearch.com

CDN Newswire